Friday, 6 November 2026European Markets

ADC SIIC Stock 25.44% Up Today

Loading stream...

(vianews) - the market ended the session with adc siic (aldv.pa) rising 25.44% to €0.07 on tuesday, after five consecutive sessions in a row of losses. cac 40 rose 0.08% to €7,282.12, following the last session's downward trend on what was a somewhat positive trend trading session today.

adc siic's last close was €0.06, 28.75% under its 52-week high of €0.08.

about adc siic

alliance developpement capital siic (adc siic) is a publicly owned real estate investment firm. the firm specializes in owning and managing residential real estate properties. it primarily invests in properties in paris and its suburbs. the firm was formerly known as ad capital sa. alliance developpement capital is based in saint-josse-ten-noode, belgium.

earnings per share

as for profitability, adc siic has a trailing twelve months eps of €-0.01.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -1.87%.

volatility

adc siic's last week, last month's, and last quarter's current intraday variation average was a negative 10.53%, a negative 3.74%, and a positive 13.36%.

adc siic's highest amplitude of average volatility was 10.53% (last week), 13.88% (last month), and 13.36% (last quarter).

yearly top and bottom value

adc siic's stock is valued at €0.07 at 22:30 est, way under its 52-week high of €0.08 and way higher than its 52-week low of €0.05.

volume

today's last reported volume for adc siic is 2000 which is 78.23% below its average volume of 9189.

more news about adc siic (aldv.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,996
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,996 facts checked against source5,552 source documents archived
Query this data → isubstrate.com